These results suggest that RencaVEGFR2-Fc and B16F10VEGFR2-Fc tumors keep growing in vivo by escaping from abrogation of the VEGF signaling pathway, even though tumor growth was delayed due to inhibition of tumor angiogenesis by VEGFR2-Fc. This evidence concerns the gene VEGFA and neoplasm.